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Background
A novel transposon tumor induction model was used to
induce cholangiocarcinoma tumors in C57BL/6 mice. In
this system, it is possible to drive immune related activities
that will lead to 1) large tumors, no clearance or response
by tumor-directed CD8+ T cells, 2) large tumors, no clear-
ance, with tumor-specific CD8+ response, or 3) CD8+
response, with tumor clearance. Analysis of proteomic
data resulting from serum samples taken pre-inoculation
and at study end were compared within and across the
three groups of mice to determine if there are detectable
differences attributable to immune functions or tumor-
immune interactions that may be used to predict outcome.
Methods
Tumors were induced using a transposon-plasmid harbor-
ing oncogenic Kras via hydrodynamic injection into the
livers of 18 mice. In addition Group 2 mice received a pri-
mer for CD8+ response and Group 3 mice received acti-
vating signals for both CD8+ and CD4+ directed
responses. Deep MALDI spectra were acquired from
mouse sera collected from mice (6 per group, 2 time
points) from 3-70KDa using a SimulTOF 100 from Virgin
Instruments in positive ion mode. The equivalent of 400K
shot spectra were created for individual mice and
analyzed.
Results
Mice in groups 1 and 2 grew intermediate or large
tumors. In Group 3, 2 mice had no detectable tumor,
1 mouse had a small tumor, and 2 mice had sizable
tumors. 30 MS features had differential behavior
between groups. Some features correlated with tumor
burden while others may be directly related to or corre-
lated with immune function.
Conclusions
Proteins in serum can be detected that measure immune
related activities. The sophisticated model developed in
the mouse system allows us to probe the serum proteome
and may translate to a better understanding of the
human immune-tumor interaction. We are actively
working to confirm the protein identifications to present
at the meeting. The study demonstrates that serum con-
tains information related to the ability of the host to clear
tumors and that the DM platform is prime for detecting
these differences. The combination of methods can be
used to identify candidate biomarkers from the geneti-
cally controlled model that can be translated and tested
in human studies with the goal of patient selection for
immunotherapies, measuring response, or to aid in iden-
tification of progression in immunotherapy treated
patients.
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